MJA: Accountability, ambition, and quantifiable action in the carbon emission reduction plans of the ten largest pharmaceutical companies in Australia: a cross‐sectional analysis
Clarity Pharmaceuticals: SECuRE trial update: 92% of pre-chemo participantsexperience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences
Invion: EXPANDED COLLABORATION & FUNDING AGREEMENT WITH MAJOR SOUTH KOREAN PHARMACEUTICAL GROUP HANLIM TO INCLUDE OESOPHAGEAL CANCER
Failure to overturn Cootamundra Pathology Lab Closure results in 24-hour strike – Health Services Union
Shortages of benzathine benzylpenicillin G in Australia highlight the need for new sovereign manufacturing capability
Syntara: Syntara’s topical anti-fibrotic drug leads to significant normalisation of skin in established scars
Recce Pharmaceuticals: Positive Phase II Data from Clinical Trial of RECCE® 327 GelSupports Accelerated Commercialisation Pathway
Imugene: Azer-cel demonstrates two additional Complete Responses in CD19 CAR-T Phase 1b Trial with 57% Complete Response Rate